VEGFA and age-related macular degeneration: Currently, there are age-related eye disease studies (AREDS), dietary supplements for early and intermediate AMD, anti-complement pathway drugs such as pegcetacoplan (Syfovre; Appellis Pharmaceuticals, Waltham, MA, USA) and avacincaptad pegol (Izervay; Iveric Bio, Cranbury, NJ, USA) for GA, and several anti-vascular endothelial growth factor (VEGF) drugs such as bevacizumab (Avastin; Genentech, San Francisco, CA, USA), ranibizumab (Lucentis, Genentech), and aflibercept (Eylea; Regeneron, Tarrytown, NY, USA) for the treatment of neovascular AMD (nAMD) and CNV.